Comparison · NCT00065260-sae
r-ATG /Cyclosporine vs Alemtuzumab (Campath-1H): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. r-ATG /Cyclosporine vs Alemtuzumab (Campath-1H): serious adverse events. Trial comparisons, record NCT00065260-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00065260-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.259 | 0.132 | 0.447 | wilson | |
| Risk in group 2 | 0.444 | 0.276 | 0.627 | wilson | |
| Risk difference, group 1 minus group 2 | -0.185 | -0.408 | 0.067 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.583 | 0.272 | 1.25 | log | |
| Odds ratio, group 1 over group 2 | 0.438 | 0.139 | 1.38 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on r-ATG /Cyclosporine than on Alemtuzumab (Campath-1H) | 5.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | r-ATG /Cyclosporine | A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).~r-ATG: Rabbit ATG 3.5mg/kg/day for consecutive 5 days~CsA: CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. | 7 | 27 | EG000 |
| Group 2 | Alemtuzumab (Campath-1H) | A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).~Campath-1H: Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day). | 12 | 27 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 3 years
Source ClinicalTrials.gov
Trial
- Title
- Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
- NCT number
- NCT00065260
- Phases
- PHASE2
- Conditions
- Aplastic Anemia
- Interventions
- Campath-1H, r-ATG, CsA
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Results first posted
- 2016-03-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00065260?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00065260-sae